Materials for Nucleic Acids Marcia Holden, Ross Haynes, Margaret - PowerPoint PPT Presentation

NIST Standard Reference Materials for Nucleic Acids Marcia Holden, Ross Haynes, Margaret Kline, John Butler National Institute of Standards and Technology Applied Genetics Group Gaithersburg, Maryland, USA SoGAT Blood Virology meeting Vilnius, Lithuania April 16 – 17 2012

NIST is a non-regulatory federal agency within the U.S. Department of Commerce. NIST’s primary mission is to promote economic growth by working with industry to develop and apply technology, measurements, and standards . Hollings Manufacturing Baldridge National Measurement and Standards Program Extension Partnership Quality Program planned and conducted in cooperation with industry and Program an outreach program focused on infrastructural technologies recognizing organizational a nationwide network of performance excellence extension centers NIST is the national measurement institute that provides hands-on technical assistance to for the United States smaller manufacturers

Applied Genetics Group Biochemical Science Division Mission Statement Advancing technology and traceability through quality genetic measurements and standard reference materials (SRMs) to aid work in • Forensic DNA testing • DNA biometrics • Clinical diagnostics – Infectious disease – genetic biomarkers – cancer-linked biomarkers

NIST DNA Reference Materials (1) Forensic Applications • STR PCR DNA Profiling (SRM 2391b) • Human Y-Chromosome DNA Profiling (SRM 2395) • Human DNA Quantitation (SRM 2372) • Mitochondrial DNA Sequencing (SRM 2392-1 SRM 2392)

NIST DNA Reference Materials (2) Clinical Diagnostics • Cytomegalovirus (SRM 2366) • Fragile X Human DNA triplet repeat (SRM 2399) • Huntington's Disease CAG Repeats (SRM 2393) Platform Testing • Heteroplasmic mtDNA Mutation Detection (SRM 2394) • DNA Sequence Library for External RNA Controls (SRM 2374)

Certified Reference Material (CRM) • Reference material (RM), one or more of whose property values are certified by a procedure which establishes its traceability to an accurate realization of the unit in which the property values are expressed, and for which each certified value is accompanied by an uncertainty at a stated level of confidence and accompanied by a certificate • Standard Reference Materials (SRMs) are CRMs certified by NIST

Traceability to the International System of Units (SI) • We want to develop characterized, stable, homogeneous nucleic acid SRMs that are traceable to the SI unit, the mole (amount of substance) • The approach to quantitative traceability is to count the number of molecules of a dilute solution of DNA in a known volume. • Our goal is to achieve accurate counting that is assay independent

Why quantitative SRMs for clinical diagnostics • To provide higher order standards for clinical diagnostics that can be used in the validation of a measurement system or to assign values to calibrants

Characterization - What and How • DNA sequence of regions of the genome is verified using Sanger sequencing • The copy number per volume is certified using digital PCR

Cytomegalovirus SRM 2366 • CMV material consists of the Towne Strain cloned into a bacterial artificial chromosome • The BAC (Towne 147) was propagated, the DNA was purified and packaged in Teflon tubes • Three different concentrations were prepared and tubes were randomly selected for quantification

Sequenced regions of the CMV genome • Regions that were chosen to be sequenced were selected because they are targets for amplification assays, based on 65 published PCR assays and information from commercial assay manufacturers • Sequencing was performed in both directions • The sequencing primers were designed to have significant overlap • The sequenced regions (total of 15,000 bp) was an exact match for the Towne strain as deposited in GenBank with the exception of one base (UL54, base 78651)

Digital PCR (dPCR) for certification of SRM 2366 • dPCR is a process where individual molecules are counted using the fluorescent signal generated by a PCR reaction when amplification of DNA occurs • This concept has been around since the 1999 but was only practical very recently with the development of microfluidic and droplet platforms where thousands of reactions are conducted simultaneously in chambers with nanoliter volumes/chamber • No calibration curve is needed

dPCR microfluidics array Pressurized valve H X 1 2 3 4 5 6 7 8 9101112 X H Samples: 1-12 Water: H Pressurized valve 765 individual chambers / panel 12 panels/chip = 9180 chambers Each chamber – 6 nL

Concentration • Saturated ≥ 1 copy in each well • Binary detection Calculate concentration • No amplification No target

Recommendations for the optimal range/765 chamber panel to minimize measurement uncertainty Institution Positive wells Targets/panel Average Copies/well Platform 200 to 700 232 to 1902 0.3 to 2.5 manufacturer National Cancer 300 to 600 382 to 1178 0.5 to 1.5 Institute USA Published* 409 to 734 585 to 2453 0.8 to 3.2 * Bhat S. et al. 2009 Anal. Bioanal. Chem. 394:457-467

dPCR Determines absolute concentration of DNA through the use of counting and statistics 550 wells with target (+) 215 wells without target (-) 765 wells / sample 550 positive wells  statistics  212 copies/ L

Poisson Distribution • Probability statistics of counting rare events • Rare  not every partition (time or space) has event (in this case, DNA) • dPCR  If you know how many wells have target you can estimate the total number of targets

Poisson Distribution Thousands of molecules over 10,000 wells More conc. means more likely to have 70% well with >1 60% Change in % negative wells with molecule/well concentration 50% 10,000 Wells (%) 40% molecules 25% 5,000 molecules of wells with >1 30% 10,000 molecules copy 30,000 molecules 20% 30,000 10% molecules 80% 0% of wells with >1 0 1 2 3 4 5 6 7 8 9 10 copy molecules/well Negative wells Positive wells

Quantification of SRM 2366 components • Each component was separately quantified using multiple digital arrays • Utilized separate assays targeting different regions of the genome, and found that the results were not significantly different – no bias • One assay was used for the rest of the measurements

Commutability • Component B of SRM 2366 was included in the Quality Control for Molecular Diagnostics (QCMD) 2010 CMV EQA program • Participants were asked to add the DNA directly to the assay rather than extracting the DNA along with the QCMD test samples • 178 participants submitted data. Laboratory developed assays were used to generate 78 datasets and commercial assays were used for 100 datasets • The median consensus value was 5.9 log10 (Component B = 6.2 log10 based on dPCR)

Commutability 0.8 Centered Histogram Kernal Density 0.7 Gaussian Model Relative Area, #Bin / (#Total Δ x) FWHM 0.6 0.5 0.4 0.3 0.2 0.1 0.0 1 2 3 4 5 6 7 8 9 Log 10 (Copies per mL)

QCMD CMV EQA - Participants & assays # Data sets Mean SD Median MADe Total Datasets 178 5.845 0.674 5.900 0.486 Conventional Commercial 5 5.670 0.672 5.854 0.872 Real-Time Laboratory developed - Total 78 5.909 0.756 6.002 0.650 Real-Time Commercial - Total 95 5.795 0.600 5.826 0.451 Commercial kit A (1) 6 5.859 0.386 5.864 0.150 Commercial kit A (2) 15 6.224 0.345 6.205 0.332 Commercial kit B 21 5.632 0.880 5.733 0.794 Commercial kit C 28 5.767 0.321 5.821 0.326 Commercial kit D 12 5.789 0.233 5.776 0.298

dPCR • Digital PCR has the possibility to be a realized reference method for quantification of nucleic acids • NIST is working with other national measurement institutions such as IRMM, LGC, NMI Australia and KRISS in collaboration with each other and through BIPM (CCQM) to validate digital PCR • NIST is working on other candidate SRMs and will be using dPCR for quantification

Thank you for the opportunity to make a presentation at SoGAT Clinical Diagnostics Team Ross Haynes Marcia Holden Margaret Kline John Butler, Group Leader